| Autor: |
Mozafar Aznab, Ali Shahriari-Ahmadi, Fatemeh Heydarpour |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Leukemia Research Reports, Vol 16, Iss , Pp 100271- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2213-0489 |
| DOI: |
10.1016/j.lrr.2021.100271 |
| Popis: |
The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular response rate and overall survival (OS). Results: About 75.9% of patients achieved deep molecular response in mean follow-up of 89.92 months. The OS rate was about 91.2%. Conclusion: There was no considerable cumulative toxicity with Imatinib long-term use. A high percent of patients had a deep molecular response. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
